FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns an isolated polypeptide that binds to a glucocorticoid-induced TNFR-related protein (GITR), including at least one GITR-binding domain (GITR-BD) containing an amino acid sequence selected from a group consisting of SEQ ID NO: 19-80. The group of inventions also concerns the isolated nucleic acid encoding the specified polypeptide; a pharmaceutical composition containing the specified polypeptide for the treatment of a malignant neoplasm in a patient.
EFFECT: group of inventions provides treatment of a malignant neoplasm in a patient.
21 cl, 15 dwg, 1 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| ANTIGEN-BINDING PROTEINS AGAINST GITR AND METHODS OF THEIR USE | 2017 |
|
RU2795625C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
